20473-06-7

Basic information

• Product Name: Cyclohexanecarbonyl azide
• CAS NO: 20473-06-7
• Molecular Formula: C7H11N3O
• Molecular Weight: 153.184
• Mol File: 20473-06-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Cyclohexanecarbonyl azide(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanecarbonyl azide(20473-06-7)
• EPA Substance Registry System: Cyclohexanecarbonyl azide(20473-06-7)

Safety Data

• Hazardous Substances Data: 20473-06-7(Hazardous Substances Data)

Upstream product

• 2043-61-0 cyclohexanecarbaldehyde 
• 66952-05-4 C₁₉H₂₁O₃P 
• 22651-87-2 cyclohexanecarboxylic acid anhydride 
• 1263290-70-5 [azido(hydroxy)methyl]cyclohexane 
• 98-89-5 Cyclohexanecarboxylic acid 
• 2719-27-9 cyclohexanylcarbonyl chloride 

Downstream Products

• 698-90-8 N'-cyclohexylurea 
• 886-59-9 N-cyclohexyl-N'-phenylurea 
• 1759-68-8 N-benzoylcyclohexylamine 
• 65513-54-4 3-cyclohexyl-1-phenyl-imidazolidine-2,4-dione 
• 1122-56-1 cyclohexylcarboxamide 
• 3173-53-3 Cyclohexyl isocyanate 
• 1407188-93-5 C₁₉H₂₅N₃O₂ 

Relevant articles and documents

Direct conversion of carboxylic acids to various nitrogen-containing compounds in the one-pot exploiting curtius rearrangement

Herein we report, a single-pot multistep conversion of inactivated carboxylic acids to various N-containing compounds using a common synthetic methodology. The developed methodology rendered the use of carboxylic acids as a direct surrogate of primary amines, for the synthesis of primary ureas, secondary/tertiary ureas, O/S-carbamates, benzoyl ureas, amides, and N-formyls, exploiting the Curtius reaction. This approach has a potential to provide a diversified library of N-containing compounds, starting from a single carboxylic acid, based on the selection of the nucleophile.

Novel tetrahydropyrido[1,2-a]isoindolone derivatives (valmerins): Potent cyclin-dependent kinase/glycogen synthase kinase 3 inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts

The development of CDK and GSK3 inhibitors has been regarded as a potential therapeutic approach, and a substantial number of diverse structures have been reported to inhibit CDKs and GSK-3β in recent years. Only a few molecules have gone through or are currently undergoing clinical trials as CDK and GSK inhibitors. In this paper, we prepared valmerins, a new family containing the tetrahydropyrido[1,2-a]isoindone core. The fused heterocycle was prepared with a straightforward synthesis that was functionalized by a (het)arylurea. Twelve valmerins inhibited the CDK5 and GSK3 with an IC50 100 nM. A semiquantitative kinase scoring was realized, and a cellular screening was done. At the end of our study, we investigated the in vivo potency of one valmerin. Mice exhibited good tolerance to our lead, which proved its efficacy and clearly blocked tumor growth. Valmerins appear also as good candidates for further development as anticancer agents.

Lithium/DTBB-induced reduction of N-alkoxyamides and acyl azides

A series of N-alkoxyamides and N-methoxy-N-methylamides (Weinreb amides) have been subjected to dealkoxylation by reductive cleavage of the N-O bond with lithium powder and a catalytic amount of DTBB (10 mol%) at room temperature, leading to the corresponding amides. When the reaction is performed under reflux conditions, the corresponding alkanes, resulting from a formal deaminocarbonylation process, are obtained. This methodology applied to acyl azides furnished the corresponding primary amides.